Cairo - Mubasher: Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) achieved a 41.4% annual increase in net profits to EGP 61.47 million in the first half (H1) of 2021 from EGP 43.47 million in H1-20.

Revenues soared to EGP 537.77 million in H1-21 from EGP 437.46 million in H1-20, according to the financial results on Monday.

As for the standalone income statements, Rameda recorded EGP 62.09 million net profits in the January-June 2021 period, compared to EGP 44.06 million in the same period last year.

During 2020, the company registered net profits of EGP 111.51 million, higher than EGP 81.67 million, including minority rights, in 2019.